There are over 80 Cannabinoids discovered so far and just a handful studied in detail.
Over the next few years we expect these molecules to be understood better and their potential harnessed significantly. The differentiator between companies will be freedom to operate, and ability to deliver these molecules effectively in the blood with best bioavailability, so their medicinal effects can be harnessed efficiently and cost-effectively.
We believe that the Cannabinoids themselves present several blockbuster opportunities and though many companies are focusing on developing cannabinoids, our MNP Platform is ideally suited to harness the potential of Cannabinoids.
Developing potent and cost-effective NanoCanabinoids is a key new focus at SGN. We expect several significant MNP based NanoCanabinoid IND filings in the next two years.